We use cookies to help provide you with the best possible online experience. Learn more

Press releases

COMPASS® receives FDA clearance and is launched

RaySearch Laboratories AB (publ.) and IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that the new dosimetry solution COMPASS® has received 510(k) clearance by the FDA and that it has been launched on the worldwide market through IBA’s business unit IBA Dosimetry.

COMPASS® is a state-of-the-art solution for quality assurance in radiotherapy that has been developed in joint cooperation between IBA Dosimetry and RaySearch Laboratories AB. It will enable the medical staff to measure and reconstruct the 3D radiation dose that was actually delivered to the patient every day during the course of treatment. This is highly valuable, particularly in advanced IMRT/IGRT treatments that aim to maximize the effective dose delivered to the tumor whilst sparing the surrounding healthy tissue.

COMPASS® will increase the safety of radiation therapy as it provides a truly independent online analysis of both the accuracy of the planned treatment as well as the dose delivered to the patient.

“The COMPASS® FDA clearance and market launch is the culmination of two years of joint effort with RaySearch Laboratories to design this novel dosimetry solution that will allow radiotherapy departments to cope with the highest treatment accuracy and reliability standards”, said Pierre Mottet, Chief Executive Officer of IBA. “We are excited to be the first company in the world to propose such an online dosimetry solution that will increase treatment efficiency and save lives”, added Mr. Mottet.

“The combination of our expertise in advanced radiotherapy software and IBA Dosimetry’s world leading dosimetry expertise, has been the ideal foundation for creating this revolutionary product”, said Johan Löf, Chief Executive Officer of RaySearch. “In addition to improving the precision, COMPASS® has the potential to significantly speed up the quality assurance process, which will enable the clinics to spend more time on treating patients and simultaneously improve safety.”

IBA Dosimetry is a fully owned division of IBA. With more than 30 years experience, it provides sophisticated and customized high-end dosimetry and quality assurance solutions for use in hospitals and by industry partners across the world. Access to national and international research partners, as well as in-house research and design activities are the foundation of successful and reliable products for a wide range of dosimetry applications in radiotherapy and radiodiagnostics.
Website: http://www.iba-dosimetry.com

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.
Website: http://www.iba-worldwide.com

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are sold through license agreements with leading partners such as Philips, Varian Medical Systems, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have been released to date and RaySearch’s software is used at over 1,200 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the MidCap segment on the OMX Nordic Exchange Stockholm.

For more information about RaySearch, please visit www.raysearchlabs.com.


Paul-Emmanuel Goethals
Director, Corporate Business Development & Investor Relations
Telephone: +32 10 47 58 16

Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30